Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 11/20 | 0.34 |
| ▸ | CNR1 | P21554 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL967097 | 0.86 | CNR2 (0.45) | HSD11B1CNR2CNR1MEN1KMT2A | |
| SCHEMBL967095 | 0.86 | CNR2 (0.45) | HSD11B1CNR2CNR1MEN1KMT2A | |
| SCHEMBL5047212 | 0.81 | CNR2 (0.39) | HSD11B1CNR2CNR1 | |
| SCHEMBL5048470 | 0.79 | BACE1 (0.34) | CNR2CNR1KDM4E | |
| SCHEMBL5047243 | 0.76 | HSD11B1 (0.33) | HSD11B1CNR2CNR1HPGD | |
| SCHEMBL964164 | 0.74 | CNR2 (0.46) | HSD11B1CNR2CNR1MEN1KMT2A | |
| SCHEMBL961865 | 0.74 | CNR2 (0.46) | HSD11B1CNR2CNR1MEN1KMT2A | |
| SCHEMBL965811 | 0.74 | CNR2 (0.46) | HSD11B1CNR2CNR1MEN1KMT2A | |
| SCHEMBL963175 | 0.74 | CNR2 (0.46) | HSD11B1CNR2CNR1MEN1KMT2A | |
| SCHEMBL966371 | 0.73 | CNR2 (0.40) | HSD11B1CNR2CNR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | ABBVIE INC. | 2008-03-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | OPRL1, OPRK1, OPRD1 | HSD11B1 2983/4885CNR2 5/4885CNR1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.